Pfizer

Trazimera

Manufacturer:

Pfizer

Trazimera HCPCS:

Q5116

HCPCS Code Descriptor:

Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg

Category:

Q Code

Trazimera NDCs:

00069-0305-01, 00069-0308-01

Primary Type:

Oncology Biosimilar

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Trazimera:

Trazimera is an Oncology Biosimilar drug manufactured by Pfizer and administered via the Intravenous route of administration. The Q Code: Q5116 is aligned to the drug Trazimera.

Trazimera (trastuzumab) is a cancer drug that is used to treat certain types of breast and stomach cancers. This medication targets the HER2 protein of the cell and can be used in combination with other medications. Trazimera is manufactured by Pfizer and is biosimilar to the medication Herceptin (J9356). Trazimera is aligned to the Q Code Q5116 and has been aligned to this code since October 2019.

ACCESS PRICING AND MORE BY REGISTERING

Q5116 Added Date:

October 1, 2019

Q5116 Effective Date:

October 1, 2019

Q5116 Termination Date:

HCPCS Active

Trazimera billing and coding information can be found through Pfizer at the link below:
Trazimera patient assistance information can be found through Pfizer Oncology Together at the URL: https://www.trazimera.com/patientresources
Trazimera prescribing information can be found at the link below:
Information regarding Trazimera’s side effects can be found at MedlinePlus